The relative influence of secondary versus primary prevention using the national cholesterol education program adult treatment panel II guidelines

被引:21
作者
Goldman, L
Coxson, P
Hunink, MGM
Goldman, PA
Tosteson, ANA
Mittleman, M
Williams, L
Weinstein, MC
机构
[1] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA
[2] Univ Groningen, Dept Hlth Sci, Groningen, Netherlands
[3] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Clin Res, Lebanon, NH 03766 USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA USA
[6] Harvard Univ, Sch Med, Boston, MA USA
[7] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
D O I
10.1016/S0735-1097(99)00260-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study was undertaken to project the population-wide effect of full implementation of the Adult Treatment Panel (ATP) II guidelines of the National Cholesterol Education Program (NCEP). BACKGROUND The ATP II has proposed guidelines for cholesterol reduction, but the long-term epidemiologic influence of its components has not been fully examined. METHODS We used a calibrated, validated simulation of the U.S. population, aged 35 to 84 years to estimate the potential for the NCEP guidelines, under varying assumptions, to reduce coronary heart disease morbidity and mortality and overall mortality from the years 2000 to 2020. RESULTS Primary prevention would yield only about half of the benefits of secondary prevention despite requiring nearly twice as many person-years of treatment. The projected increase in quality-adjusted years of life per year of treatment for secondary prevention was 3- to 12-fold higher than for primary prevention. To yield population-wide epidemiologic benefits equivalent to NCEP recommendations for secondary prevention, primary prevention would require a nearly sixfold increase in the number of persons treated compared with NCEP recommendations. All benefits of universal success of the NCEP primary prevention "screen and treat" guidelines could be achieved by a 11 mg/dl (8%) population-wide reduction in low-density lipoprotein cholesterol levels among persons without preexisting coronary heart disease. CONCLUSIONS The NCEP guidelines for targeted primary prevention can be a useful component of a rational public health strategy, but only as a complement to the more appealing strategies of secondary prevention and "across-the-board" programs to lower all cholesterol levels. (J Am Coil Cardiol 1999;34:768-76) (C) 1999 by the American College of Cardiology.
引用
收藏
页码:768 / 776
页数:9
相关论文
共 50 条
[1]  
[Anonymous], 1991, ARCH INTERN MED, V151, P1071, DOI 10.1001/archinte.151.6.1071
[2]   TRENDS IN SERUM-CHOLESTEROL LEVELS FROM 1980 TO 1987 - THE MINNESOTA HEART SURVEY [J].
BURKE, GL ;
SPRAFKA, JM ;
FOLSOM, AR ;
HAHN, LP ;
LUEPKER, RV ;
BLACKBURN, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) :941-946
[3]   REPORT OF THE EXPERT PANEL ON POPULATION STRATEGIES FOR BLOOD CHOLESTEROL REDUCTION - A STATEMENT FROM THE NATIONAL CHOLESTEROL EDUCATION-PROGRAM, NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NATIONAL-INSTITUTES-OF-HEALTH [J].
CARLETON, RA ;
DWYER, J ;
FINBERG, L ;
FLORA, J ;
GOODMAN, DS ;
GRUNDY, SM ;
HAVAS, S ;
HUNTER, GT ;
KRITCHEVSKY, D ;
LAUER, RM ;
LUEPKER, RV ;
RAMIREZ, AG ;
VANHORN, L ;
STASON, WB ;
STOKES, J .
CIRCULATION, 1991, 83 (06) :2154-2232
[4]  
*DEP HLTH HUM SERV, 1987, NIH PUBL
[5]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[6]   Indications for cholesterol-lowering medication: comparison of risk-assessment methods [J].
Durrington, PN ;
Prais, H ;
Bhatnagar, D ;
France, M ;
Crowley, V ;
Khan, J ;
Morgan, J .
LANCET, 1999, 353 (9149) :278-281
[7]   LONG-TERM COST-EFFECTIVENESS OF VARIOUS INITIAL MONOTHERAPIES FOR MILD TO MODERATE HYPERTENSION [J].
EDELSON, JT ;
WEINSTEIN, MC ;
TOSTESON, ANA ;
WILLIAMS, L ;
LEE, TH ;
GOLDMAN, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (03) :407-413
[8]   THE BEAVER DAM HEALTH OUTCOMES STUDY - INITIAL CATALOG OF HEALTH-STATE QUALITY FACTORS [J].
FRYBACK, DG ;
DASBACH, EJ ;
KLEIN, R ;
KLEIN, BEK ;
DORN, N ;
PETERSON, K ;
MARTIN, PA .
MEDICAL DECISION MAKING, 1993, 13 (02) :89-102
[9]  
Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013
[10]  
GIFFORD RW, 1993, ARCH INTERN MED, V153, P154